An observational study in Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant and Nephrotic Syndrome in Children, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Not yet recruiting. Open to participants aged Up to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-30.
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational
Idiopathic Nephrotic Syndrome is a rare disease of the kidneys, which typically affects children. For most affected children there is the need of a prolonged treatment with drugs reducing the activity of the immune system, also resulting in many side effects. Those patients, who do not respond to treatment, are at risk of kidney damage and of dialysis or kidney transplantation. It is currently impossible to predict the response to treatment, leading to unnecessary therapies with side effects as well as unclear prognosis in the affected children. The response of the idiopathic nephrotic syndrome to medications acting on the immune system explains its important role in the occurrence of the disease.
With this study we aim to obtain predictors of the response to treatment right at the beginning of the disease, to adapt the therapy avoiding needless side effects. This will be done evaluating the blood and urine of affected children using state of the art molecular characterisation. We will evaluate the genetic predisposition, the cell trait changes and the presence of molecules in blood and urine that may affect the interaction between the immune system and the kidneys. We expect that the findings will improve treatment of children with idiopathic nephrotic syndrome and reduce the number of children suffering from unnecessary drugs related side effects.
The PRECISE study (Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome) is an innovative, multicenter research project focused on advancing our understanding of pediatric nephrotic syndrome (NS) and improving treatment outcomes for affected children across Europe. This project, which involves multiple European institutions, centers around discovering predictive biomarkers using advanced genetic, transcriptomic, and secretome multiomics methods. Nephrotic syndrome, a complex kidney disease that primarily impacts children, can lead to significant health challenges and often necessitates prolonged treatment with immunosuppressive drugs that carry side effects.
Overview of Nephrotic Syndrome
Nephrotic syndrome is characterized by symptoms such as proteinuria (excessive protein in the urine), hypoalbuminemia (low blood albumin levels), edema (swelling), and hyperlipidemia (high blood lipids). Pediatric nephrotic syndrome, known for its unpredictable nature, is categorized as Idiopathic Nephrotic Syndrome (INS) and affects around 2-7 children per 100,000 each year. While some children respond well to steroid treatment (steroid-sensitive), a significant proportion may become steroid-resistant, risking severe kidney damage that may lead to dialysis or even kidney transplant.
Why This Study is Important
Currently, it is challenging to predict which children will respond to treatment, how their disease will progress, or which children may experience repeated relapses. The standard treatment with immunosuppressive drugs, although effective for some, can bring numerous side effects, especially with prolonged use. Therefore, one of the most pressing unmet needs in pediatric nephrology is to develop early predictive biomarkers for individualized treatment plans, ultimately reducing unnecessary drug exposure and improving long-term outcomes.
The PRECISE study is designed to fill this critical gap by identifying genetic and molecular markers that can help clinicians:
Objectives of the Study
The primary goal of the PRECISE study is to create a predictive model for differentiating children with Steroid-Resistant Nephrotic Syndrome (SRNS) or Steroid-Dependent Nephrotic Syndrome (SDNS) from those with Infrequent Relapsing Nephrotic Syndrome (IRNS) right at the onset of the disease. This model will integrate various data sources, including omics, genetic, and clinical information, to produce a reliable "biomarker signature" that can guide therapeutic decisions from the start.
The study has several secondary objectives, including:
Study Design and Methodology
The PRECISE study is an open, multicenter, observational study. It will enroll a total of 310 children diagnosed with INS and an additional control group of 40 healthy children. The study is structured as follows:
Key Elements of the Study Protocol
Inclusion Criteria for Participants
For the main study group, children must be aged between 1 and 18 years and have a clinical diagnosis of idiopathic nephrotic syndrome. They should not have undergone any previous treatment for INS and must meet specific criteria for disease markers, such as proteinuria and hypoalbuminemia. A validation cohort includes children with similar characteristics but who have already been treated, while a control group comprises healthy children with no proteinuria and minor congenital kidney conditions.
Data Collection and Sampling
At each assessment visit, clinical data will be gathered, including physical exam results, medical history, vital signs, and laboratory values. Biological samples (blood and urine) will also be collected and stored at centralized biobanking facilities, with samples being analyzed for a wide range of molecular markers. The study uses high-level biostatistics and bioinformatics to interpret the complex data, aiming to provide a multidimensional view of each participant's health profile.
Analysis and Expected Outcomes
Using advanced statistical techniques and machine learning algorithms, researchers will analyze differences in genetic, immune, and molecular markers among the different patient groups. The primary endpoint is to develop molecular signatures predictive of disease progression, which can differentiate between SRNS, SDNS, and IRNS groups. Secondary endpoints include:
Impact and Implications
The PRECISE study represents a major step forward in pediatric nephrology by leveraging cutting-edge scientific methods to address the pressing challenges faced by children with nephrotic syndrome. By identifying biomarkers that predict treatment response and disease progression, this study can help tailor treatments to each child's needs, reducing the risk of adverse side effects and improving overall outcomes.
Consortium and Collaborating Institutions
The project is led by the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy, under the guidance of Principal Investigator Prof. Giovanni Montini. It brings together several renowned research centers and universities across Europe, each contributing unique expertise in pediatric nephrology, genetics, and molecular biology. Key partners include Heidelberg University, University Hospital of Cologne, Medical University of Gdansk, Istanbul University, and Vilnius University, along with patient advocacy organizations such as NephCEurope and various national nephrology groups.
Through this consortium, the study integrates expertise and resources from across Europe, ensuring a robust and comprehensive approach to this challenging area of pediatric medicine.
Summary
In summary, the PRECISE study is a pioneering effort to improve the diagnosis, prognosis, and treatment of pediatric nephrotic syndrome through the identification of precise molecular biomarkers. This study not only seeks to benefit children affected by nephrotic syndrome today but also lays the groundwork for future research in rare kidney diseases. By aligning clinical care with the latest in genetic and molecular science, the PRECISE study aims to provide new hope to families affected by this chronic and often debilitating condition.
191 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.
This study's planned enrollment of 350 is above the median of 125 across 59 observational studies indexed under Nephrotic Syndrome.
Browse Nephrotic Syndrome studies →Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 233 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study participants will be selected from a population of pediatric patients with idiopathic nephrotic syndrome (INS) who are treatment-naive and present with clinical symptoms such as proteinuria, hypoalbuminemia, and edema. These patients, aged 1 to 18 years, are typically referred to specialized nephrology clinics or tertiary care centers across Europe, where they receive initial diagnosis and follow-up care.
The participant pool is drawn from both primary recruiting centers, which are large pediatric nephrology units with established expertise in managing nephrotic syndrome, and additional collaborating centers within the European ERKNet and ESCAPE Networks. This setting ensures a broad representation of pediatric INS cases across various European regions, enhancing the study's generalizability. Additionally, a control group of age-matched children without nephrotic syndrome is included, selected from children undergoing minor urological procedures in these clinical settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort comprises 110 children diagnosed with idiopathic nephrotic syndrome (INS) who are treatment-naive at enrollment. The participants will receive a standard induction therapy with prednisone or prednisolone and will be followed for 12 months. During this period, blood and urine samples will be collected at various points (enrollment, 6 weeks, 6 months, and 12 months) and in cases of relapse. The goal is to monitor disease progression and classify patients based on their response to therapy, specifically identifying subtypes such as steroid-resistant, steroid-dependent, and infrequent relapsing nephrotic syndrome .
This cohort consists of 40 age-matched children without nephrotic syndrome, selected from individuals undergoing minor urological surgical procedures. These participants will provide baseline control samples (blood and urine) for comparison with the INS patients' samples. This group allows researchers to identify molecular characteristics unique to INS by contrasting them with data from healthy children .
This group includes 200 INS patients who have previously received treatment and are part of the larger validation phase. This cohort will be used to confirm the biomarkers and molecular profiles identified in the main cohort. The aim is to generalize findings and ensure that identified biomarkers are consistent across a broader population. Samples will be collected during relapse and remission, aligning with the study's focus on validating predictive biomarkers of disease course and therapeutic response .
Predictive Molecular Signature of INS Progression
Identification of distinct molecular characteristics predictive of the progression of idiopathic nephrotic syndrome (INS). This includes differentiating between steroid-resistant nephrotic syndrome (SRNS), steroid-dependent nephrotic syndrome (SDNS), and infrequent relapsing nephrotic syndrome (IRNS). Measure Type: Analysis of genetic/epigenetic background, immune status, and vesicular proteome/transcriptomic profile. Goal: Develop a biomarker-based predictive model that assists in early classification of INS subtypes.
Time frame: Up to 1 year from enrollment after initial diagnosis.
Genetic and Epigenetic Risk Factors
Quantification of kidney- and immune-related genetic variants associated with INS incidence and disease progression. Measure Type: Number of risk variants in kidney and immune-related genes, along with methylation profiles showing hypomethylated and hypermethylated regions related to immune function and progression to kidney failure .
Time frame: Up to 6 months from enrollment after initial diagnosis.
Immune System Alterations
Analysis of adaptive immune system changes in INS patients. Measure Type: Proportion and absolute numbers of B and T cell subpopulations, changes in immune cell subset genes, and phosphorylation sites in primary immune cells. Goal: Examine immune profiles associated with disease subtypes to better understand immunologic drivers of INS .
Time frame: Up to 1 year from enrollment after initial diagnosis.
Proteomic Patterns in Serum and Urine
Identification of unique protein profiles in serum and urine that correlate with different INS subtypes. Measure Type: Analysis of extracellular vesicle concentration and size in urine, surface proteome of extracellular vesicles, and serum proteome characteristics in different INS groups. Goal: Detect specific proteomic markers linked to disease phenotype and progression .
Time frame: Up to 1 year from enrollment after initial diagnosis.
Molecular Profile of Healthy Control Group
Comprehensive molecular characterization of healthy children to establish a baseline for comparison with INS patients. Measure Type: Similar profiling as for INS patients, focusing on genetic and proteomic markers. Goal: Differentiate between disease-specific and baseline molecular signatures .
Time frame: At a single time point during enrollment.
No study locations are listed for this record.
Plan to share: No — The PRECISE study does not plan to share Individual Participant Data (IPD). This decision prioritizes the protection of participant confidentiality and aligns with the study's ethical guidelines, ensuring that sensitive genetic, transcriptomic, and proteomic information remains secure. As such, no IPD collected throughout the trial will be made available publicly or for secondary research purposes.
Start is estimated for Feb 2025; primary completion for Dec 2027, 33 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico →